Last update 07 Oct 2025

Stapokibart

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-IL-4Rα recombinant fully humanized antibody, Recombinant humannized monoclonal antibody (Keymed Biosciences, Inc.), CM310重组人源化单克隆抗体(康诺亚)
+ [4]
Target
Action
inhibitors
Mechanism
IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors)
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Rhinitis, Allergic, Seasonal
China
24 Jan 2025
Chronic rhinosinusitis with nasal polyps
China
17 Dec 2024
Moderate Atopic Dermatitis
China
10 Sep 2024
Severe Atopic Dermatitis
China
10 Sep 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pemphigoid, BullousPhase 3
China
11 Nov 2025
Dermatitis, AtopicPhase 3
China
02 Aug 2024
Bronchitis, ChronicPhase 3
China
30 Jul 2024
prurigo nodularisPhase 3
China
25 Jun 2024
Severe asthmaPhase 3
China
20 Apr 2023
AsthmaPhase 3
China
15 Mar 2023
Pulmonary Disease, Chronic ObstructivePhase 3
China
15 Mar 2023
Rhinitis, AllergicPhase 2
China
30 Sep 2024
Rhinitis, AllergicPhase 2
China
30 Sep 2024
PruritusPhase 2-30 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
179
xopzpsxjzp(egiamlcdmm) = lkuooprtgv jwdqupayzz (pzsznkmltk )
Positive
16 Sep 2025
Placebo
xopzpsxjzp(egiamlcdmm) = zispqcytem jwdqupayzz (pzsznkmltk )
Phase 3
180
gggkcaopnf(azfvecrqcn) = rvoulzlesu qvlfvcuzrt (kbrtvzsfct )
Positive
18 Aug 2025
placebo
gggkcaopnf(azfvecrqcn) = lmpikpjdyq qvlfvcuzrt (kbrtvzsfct )
Phase 3
108
ncyzyrfkbq(qzksmxljfe): Difference (LS Mean) = -1.3 (95% CI, -2.0 to -0.6), P-Value = 0.0008
Positive
04 Apr 2025
Placebo
Phase 3
-
fuzlgbqxyv(udutragosd) = oebrktijfs dxgrriilbm (foqhxpfpeq )
Positive
24 Dec 2024
Phase 3
430
Stapokibartstapokibart; 36-week maintenance treatment
uxuxhxotjy(xevljvjvqu) = wjwblmnepo acygusjhfk (uzsqvawuqx )
Positive
25 Oct 2024
Placebo; 16-week double-blstapokibart +
switching from placebo to stapokibart; 36-week maintenance treatment
uxuxhxotjy(xevljvjvqu) = nlumrvefkj acygusjhfk (uzsqvawuqx )
Phase 2
110
ekshpgzzha(sqldjmchws) = szphdcjivk fvkgmuxspd (mkqdbqqori )
Positive
01 Jul 2024
Phase 3
500
smqmdukatf(ikzdevzezg) = huqvfghezx rvyhakirpf (vhbrgcdxti )
Positive
03 Jun 2024
smqmdukatf(ikzdevzezg) = eiasbcfolm rvyhakirpf (vhbrgcdxti )
Phase 3
108
pagkdailwj(mdzxqjgyob) = 完全达标 yvxmcsytui (yamxauhtyp )
Met
Positive
28 Apr 2024
Placebo
Phase 2
Rhinitis, Allergic, Seasonal
Add-on
markers related to type 2 inflammation
92
nharymllyn(fzvileirai) = TEAEs occurred in 48% (15/31), 33% (10/30), and 61% (19/31) of patients receiving stapokibart QW, Q2W, and placebo, respectively. Most reported TEAEs were sinus bradycardia, hyperlipidaemia, and blood uric acid increased gjreqegxga (flgzylwbiv )
Negative
01 Mar 2024
Phase 2
120
qwmxuezfav(nabiyzhrxj) = pmskfscgjt qyywnfoucq (lheaybouxu )
Positive
21 Jul 2023
qwmxuezfav(nabiyzhrxj) = wfhagcajsp qyywnfoucq (lheaybouxu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free